Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 30, 2021
Distillery Therapeutics

Inhibiting the H3K36me2 pathway for a pediatric brain cancer subtype

DISEASE CATEGORY: Cancer
INDICATION: Brain cancer Targeting the NSD1/NSD2-H3K36me2-PSIP1/HDGF2 pathway could treat diffuse intrinsic pontine glioma (DIPG) harboring the histone H3K27M driving
BioCentury | Jun 16, 2014
Clinical News

OCU100 regulatory update

BioCentury | Jun 16, 2014
Company News

Ocugen, University of Colorado deal

BioCentury | Apr 17, 2014
Distillery Therapeutics

Indication: Cancer

BioCentury | May 30, 2013
Distillery Therapeutics

Indication: Ophthalmic disease

BioCentury | Sep 27, 2010
Company News

Pfizer, Catholic University Leuven deal

BioCentury | Sep 8, 2006
Clinical News

p75 critical for HIV integration

BioCentury | Feb 17, 2003
Company News

Hybrigenics SA other research news

BioCentury | Feb 17, 2003
Tools & Techniques

Hybrigenics: Transcriptional discrimination

Items per page:
1 - 9 of 9
Help Center
Username
Request a Demo
Request Training
Ask a Question